Diseases and Conditions

The nonclinical drug candidates that Akros Pharma takes into clinical development come out of the research conducted by the Central Pharmaceutical Research Institute (CPRI) of JT Pharmaceuticals in Osaka, Japan. The current development focus for Akros reflects the research focus at CPRI.

Currently, CPRI and Akros are working to develop new therapeutics for the following disease states:




Code (Generic Name)





Potential Indication





Dosage form





Mechanism





Stage


JTE-051
  • Autoimmune diseases
  • Allergic diseases
Oral Interleukin-2 inducible T cell kinase inhibitor Suppresses overactive immune response via inhibition of the signal to activate T cells related to immune response. Phase2
JTT-251
  • Type 2 diabetes mellitus
Oral PDHK inhibitor Decreases blood glucose by activation of pyruvate dehydrogenase (PDH) related to carbohydrate metabolism. Phase1
JTT-662
  • Type 2 diabetes mellitus
Oral SGLT1 inhibitor Suppresses postprandial hyperglycemia and normalizes blood glucose level via inhibition of SGLT1 Phase1
JTE-761
  • Autoimmune diseases
  • Allergic diseases
Oral RORγ antagonist Suppresses overactive immune response via inhibitation of RORγ related to Th 17 activation Phase1

Clinical trial phase presented above is based on the first dose.